Immunology Daily Report: 01/23/2024

A phase 2 randomized study investigated the effect of IV nipocalimab in 68 patients with generalized myasthenia gravis (gMG) and found a significant dose-dependent reduction in MG-ADL scores at day 57, with similar incidences of treatment-emergent adverse events (TEAEs) compared to placebo (1).

Reference

Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, Quan D, Sevilla T, Jouvin MH, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu Y, Arroyo S; Vivacity-MG Phase 2 Study Group. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study. Neurology. 2024 Jan 23;102(2):e207937. doi: 10.1212/WNL.0000000000207937. Epub 2023 Dec 21. PMID: 38165333.